AMAG Pharmaceuticals, Inc announced it has completed the sale of its rights to Intrarosa® (prasterone) to Millicent Pharma Limited, a global pharmaceutical company formed by the Millicent Pharma management team and The Carlyle Group in 2018 that specializes in women’s health and menopause-related conditions, for up to $125 million, including upfront fixed consideration of $20 million and contingent, sales-based milestone payments of up to $105 million.
source https://www.pharmatutor.org/pharma-news/2020/amag-pharmaceuticals-completes-sale-of-its-rights-to-intrarosa-to-millicent-pharma-for-up-to-125-million-doller
No comments:
Post a Comment